AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01198210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: local peritonsillar infiltration of ketamine (0.5 mg/kg)
Study NCT01198210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: local peritonsillar infiltration dexamethasone (0.2 mg/kg))
Study NCT01198210 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine-dexamethasone
Description: local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
Study NCT02326168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Intravesical instillation for non-muscle invasive bladder cancer
Study NCT02461290 — intervention group
Intervention type: RADIATION
Intervention: Chemotherapy
Study NCT02461290 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Study NCT01304992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - low dosage
Description: The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
Study NCT01304992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - low dosage
Description: The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
Study NCT01304992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - high dosage
Description: The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
Study NCT01304992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - high dosage
Description: The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
Study NCT02709551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV_Bfb
Study NCT02709551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBI
Study NCT02709551 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MBI_HRV_Bfb
Study NCT01848977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular occlusion test
Description: Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
Study NCT01848977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vascular occlusion test
Description: Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
Study NCT00493324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: Intramuscular
Study NCT01660672 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LEVETIRACETAM
Description: liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
Study NCT04153175 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
Description: Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
Study NCT04153175 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)
Description: Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00969592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glulisine, insulin aspart
Description: single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
Study NCT00969592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart, insulin glulisine
Description: single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
Study NCT04530487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV and PO
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04530487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO
Study NCT04530487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT02383888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Study NCT02383888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04629391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total shoulder arthroplasty
Description: A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
Study NCT04629391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty
Description: A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
Study NCT02494973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin HAI
Description: Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
Study NCT02494973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin IV
Description: Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
Study NCT02494973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
Study NCT02494973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01910324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy Cross-Systems
Description: Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
Study NCT01910324 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Services as Usual
Description: Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
Study NCT03775265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03775265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo a TURBT
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo a TURBT
Study NCT02635113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Synchronized Vibration System
Description: A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
Study NCT03067597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: The DVI contains 10 mg dinoprostone
Study NCT00044304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST > 2.5 or bilirubin > 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.
Study NCT00044304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST > 2.5 or bilirubin > 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
Study NCT03281603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM complete denture
Description: complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
Study NCT03281603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM complete denture
Description: complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
Study NCT05421117 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic adnexal mass extraction
Description: Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
Study NCT03529305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Receive rTMS treatment to the primary motor cortex (M1)
Study NCT00493324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyvalent pneumococcal vaccine
Description: Injection
Study NCT03529305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Receive physical therapy
Study NCT00559455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
Study NCT00559455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
Study NCT00559455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m², Day 1 and Day 2; Every 2 weeks
Study NCT03529305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Receive physical therapy
Study NCT01664741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch - transdermal
Description: 21 mg patch
Study NCT01664741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04178525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChitoCare gel
Description: ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
Study NCT04178525 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
Study NCT04047706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205 25mg
Description: Given PO
Study NCT04047706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04047706 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04047706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT04047706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205 50 mg
Description: Given PO
Study NCT04047706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205 100 mg
Description: Given PO
Study NCT03563742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg
Description: Participants will receive rilpivirine 25 mg tablet orally once daily.
Study NCT03563742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
Description: Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
Study NCT03193970 — intervention group
Intervention type: BEHAVIORAL
Intervention: Post-Operative Recovery Registry
Description: Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
Study NCT03722420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
Study NCT03722420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
Study NCT03284827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: edoxaban (60 mg once daily \[OD\]) for at least 6 months
Study NCT03284827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
Study NCT03777878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
Study NCT02013115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
Study NCT02605850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: All subjects will consume ground beef patty meal with water at the baseline visit.
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03103321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03394066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS (MagVenture MagPro 100 with MagOption)
Description: TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
Study NCT03538652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JITAI
Description: Just-In-Time Adaptive Intervention delivered via smartphone app
Study NCT03538652 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02605850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate Juice will be taken 1/day for 4 weeks.
Study NCT02605850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate extract
Description: Pomegranate extract will be taken 1/day for 4 weeks.
Study NCT02867956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
Study NCT02867956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
Study NCT01583868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L RD2135-01 lens C
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
Study NCT01583868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L RD2135-01 lens D
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
Study NCT01583868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision2
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
Study NCT01583868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
Study NCT04132154 — intervention group
Intervention type: PROCEDURE
Intervention: Convective Forced-Air Active Warming
Description: Underbody Blanket Model 585 of the 3M BairHugger Series
Study NCT00474799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNS075
Description: MNS075 7.5mg q1h MNS075 15mg q3h
Study NCT02205515 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: Everolimus is a novel derivative of rapamycin.
Study NCT03388840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived stem cells suspention
Description: application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
Study NCT03388840 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
Study NCT04178421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized training program
Description: Eye-gaze fixation computer based training program
Study NCT04178421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pac-Man, Zookeeper, Tetris
Study NCT02220452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music listening during anesthesia
Description: In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia